|
 |
palonosetron hydrochlorideThis page contains recent news articles, when available, and an overview of palonosetron hydrochloride but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Eisai's Aloxi (palonosetron hydrochloride) injection, www.aloxi.com, is now approved for the prevention of postoperative nausea and vomiting (PONV) for up ... $9.94 - Drug Topics - Alacra Store Point-I Co Ltd acquires Alox Co Ltd (pending) - Deal Snapshot - … - Sep 25, 2008 New Drug Application (sNDA) for Alox i (palonosetron hydrochloride) Injection for the…New Drug Application (sNDA) for Alox i (palonosetron hydrochloride) ... Pay-Per-View - deals - Alacra Store Alox Co Ltd acquires a minority stake in Point-I Co Ltd - Deal... - Sep 30, 2008 New Drug Application (sNDA) for Alox i (palonosetron hydrochloride) Injection for the…New Drug Application (sNDA) for Alox i (palonosetron hydrochloride) ... Pay-Per-View - deals - Alacra Store Press Release: Helsinn and Therabel Pharma Announce a License … - Feb 8, 2006 PR Newswire Europe; February 16, 2006 ; 700+ words ... ... exclusive License and Distribution rights of Aloxi(R) (Palonosetron hydrochloride) in the Nordic ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: HELSINN Announces Aloxi sNDA for PONV Accepted for … - Jul 10, 2007 HELSINN's Top Management today announced that the supplemental New Drug Application (sNDA) for Aloxi(R) (palonosetron hydrochloride) Injection for the ... Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: Helsinn Birex Therapeutics Ltd. Announces the Launch... - May 24, 2005 Helsinn Birex Therapeutics Ltd. Announces the Launch of the New 5-HT3 Receptor Antagonist ALOXI(R) (Palonosetron hydrochloride) EU/1/04/306/001 in Ireland. Pay-Per-View - PR Newswire Europe - HighBeam Research Press Release: FDA Approves Aloxi(R) (Palonosetron HCl) Injection for... - Mar 3, 2008 PR Newswire Europe; February 16, 2006 ; 700+ words ... ... exclusive License and Distribution rights of Aloxi(R) (Palonosetron hydrochloride) in the Nordic ... Pay-Per-View - PR Newswire Europe - HighBeam Research … been granted a labeling change for Aloxi (palonosetron hydrochlorid... - Oct 8, 2007 Palonosetron hydrochloride is approved for prevention of the acute nausea and vomiting of initial and repeat courses of moderately and highly emetogenic ... Free with registration - Drug Topics - AccessMyLibrary.com … Positive Phase 3 Results for Aloxi(R)(Palonosetron Hydrochloride) ... - Dec 14, 2006 Helsinn Announces Positive Phase 3 Results for Aloxi(R)(Palonosetron Hydrochloride) Injection for the Prevention of Post Operative Nausea & Vomiting. from ... Pay-Per-View - PR Newswire Europe - HighBeam Research MGI PHARMA and HELSINN Announce Aloxi sNDA for PONV Accepted … - Jul 9, 2007 MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine ... RedOrbit MGI PHARMA Updates Outlook for First Quarter - Apr 13, 2006 Sales of Aloxi(R) (palonosetron hydrochloride) Injection are expected to total approximately $63 million for the first quarter of 2006. ... Genetic Engineering News - Genetic Engineering News (press release) … Positive Phase 3 Results for Aloxi(R) (Palonosetron Hydrochloride)... - Dec 14, 2006 ...completion of two phase 3 trials of Aloxi(R) (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV). ... Genetic Engineering News - Genetic Engineering News (press release) Article: Helsinn and ribosepharm Announce a License Agreement for … - Feb 1, 2005 Administration (FDA) has approved Aloxi(TM) (palonosetron hydrochloride ... HELSINN's submission of the Aloxi(TM) New Drug Application ... ... Pay-Per-View - PR Newswire Europe - HighBeam Research Helsinn and MGI Pharma announce sNDA for ALOXI Capsules accepted … - Mar 1, 2008 MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine ... presseportal.ch MGI PHARMA Reports Third Quarter 2006 Financial Results. - Oct 18, 2006 ...proprietary products that address the unmet needs of patients. MGI PHARMA markets Aloxi[R] (palonosetron hydrochloride) Injection, Dacogen[TM. $4.95 - Business Wire - ECNext FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of … - Aug 23, 2008 ALOXI (palonosetron hydrochloride) injection 0.25 mg, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, has been available in the United States for ... RedOrbit Press Release: HELSINN Announces Submission of Supplemental New … - May 7, 2007 About Aloxi(R) (palonosetron hydrochloride) Injection. Aloxi is approved by the U.S. FDA for the prevention of acute nausea and vomiting associated with ... Pay-Per-View - PR Newswire Europe - HighBeam Research MGI PHARMA and HELSINN Announce sNDA for Aloxi Capsules … - Jan 3, 2008 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA and HELSINN Announce Submission of Supplemental … - Oct 29, 2007 MGI PHARMA markets Aloxi([R]) (palonosetron hydrochloride) Injection, Dacogen([R]) (decitabine) for Injection, and Gliadel([R]) Wafer (polifeprosan 20 with ... $4.95 - Business Wire - ECNext MGI PHARMA EXPECTS $78 MILLION TOTAL REVENUE FOR FIRST … - May 1, 2006 Sales of Aloxi(R) (palonosetron hydrochloride) Injection are expected to total approximately $63 million for the first quarter of 2006. ... $4.95 - Biotech Financial Reports - ECNext MGI PHARMA and HELSINN HEALTHCARE SA Announce Patent … - Feb 13, 2007 MGI PHARMA markets Aloxi([R]) (palonosetron hydrochloride) Injection, Dacogen([R]) (decitabine) for Injection, and Gliadel([R]) Wafer (polifeprosan 20 with ... $4.95 - Business Wire - ECNext MGI PHARMA and HELSINN Announce Aloxi sNDA for PONV Accepted … - Mar 4, 2008 MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine ... businesswire.com Press Release: FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for … - Aug 23, 2008 ALOXI (palonosetron hydrochloride) injection 0.25 mg, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, has been available in the United States for ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Helsinn Healthcare SA Announces the Launch of Aloxi(R)... - Feb 11, 2008 Administration (FDA) has approved Aloxi(TM) (palonosetron hydrochloride ... HELSINN's submission of the Aloxi(TM) New Drug Application ... ... Pay-Per-View - PR Newswire Europe - HighBeam Research MGI PHARMA Analyst and Institutional Investor Event to Be Webcast on ... - May 25, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... businesswire.com Press Release: Palonosetron: The Long-Lasting Antiemetic Action Finds... - Sep 12, 2008 PR Newswire Europe; January 12, 2005 ; 700+ words ... ... rights for ALOXI(r) (Palonosetron hydrochloride) in Indonesia ... nausea and vomiting (CINV) ... Pay-Per-View - PR Newswire Europe - HighBeam Research MGI PHARMA Fourth Quarter and Year End 2004 Financial Results; … - Feb 9, 2005 MGI PHARMA markets Aloxi(TM) (palonosetron hydrochloride) injection, Salagen(R) Tablets (pilocarpine hydrochloride), and Hexalen(R) (altretamine) capsules ... businesswire.com Press Release: FDA Approves Aloxi(R) (Palonosetron HCL) Injection for... - Mar 3, 2008 PR Newswire; December 23, 2003 ; 700+ words ... ... posters and one published abstract describing Aloxi(TM) (palonosetron hydrochloride) injection . ... Pay-Per-View - PR Newswire - HighBeam Research Eisai Gaining Cancer Portfolio In $3.9B MGI Acquisition - Dec 11, 2007 The MGI deal adds five more marketed cancer products to the mix: Aloxi (palonosetron hydrochloride), for chemotherapy-induced nausea and vomiting (CINV); ... BioWorld Online - BioWorld Online James Hawley Joins MGI PHARMA As Senior Vice President; To Be … - Jan 31, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate capsules), Salagen(R) Tablets (pilocarpine ... $4.95 - Business Wire - ECNext MGI PHARMA Second Quarter 2005 Financial Results Conference Call to … - Jul 6, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... $4.95 - Business Wire - ECNext Guilford Pharmaceuticals Stockholders Vote to Approve MGI PHARMA … - Sep 29, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Gliadel(R) wafer (polifeprosan 20 with carmustine implant), and Kadian(R) (sustained ... $4.95 - PR Newswire - ECNext Reports Activity for MGI PHARMA INC. - Oct 19, 2006 ...driven primarily by higher sales of Aloxi (palonosetron hydrochloride) Injection, the commercial launch of Dacogen(TM) (decitabine) for Injection, ... Free with registration - M2 Presswire - AccessMyLibrary.com MGI PHARMA to Present at the 2005 Banc of America Securities Health … - May 16, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate capsules), Salagen(R) Tablets (pilocarpine ... $4.95 - Business Wire - ECNext Helsinn Healthcare et MGI PHARMA annoncent le dépôt d'une demande … - Oct 31, 2007 MGI PHARMA commercialise Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection, et Gliadel® Wafer (polifeprosan 20 with ... presseportal.ch Palonosetron (Aloxi): a second-generation 5-H[T.sub.3] receptor … - Oct 1, 2006 In July 2003, the Food and Drug Administration approved palonosetron hydrochloride injection for the treatment of chemotherapy-induced nausea and vomiting ... Free with registration - Baylor University Medical Center... - AccessMyLibrary.com Approvable Letter Received from the FDA for Dacogen(TM) (Decitabine) ... - Sep 1, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, KADIAN(R) (sustained release morphine capsules), Salagen(R) Tablets (pilocarpine ... businesswire.com MGI PHARMA to Present at the 23rd Annual JPMorgan Healthcare … - Jan 6, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA to Present at the UBS Global Life Sciences Conference. - Sep 19, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Reports First Quarter 2007 Financial Results. - Apr 18, 2007 During the first quarter of 2007, US sales of Aloxi([R]) (palonosetron hydrochloride) Injection totaled $47.3 million compared to $63.3 million in the first ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Announces Aquavan NDA Accepted for Review by US … - Dec 17, 2007 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with ... Genetic Engineering News - Genetic Engineering News (press release) MGI, SuperGen Get Dacogen Approvable Letter, Have Hope - Sep 6, 2005 MGI's portfolio includes four marketed products: Aloxi (palonosetron hydrochloride) injection, Kadian (sustained-release morphine capsules), Salagen tablets ... BioWorld Online - BioWorld Online MGI PHARMA Announces Commercial Availability of Dacogen(TM) ( … - May 26, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... RedOrbit Handbook on Injectable Drugs – 14th Edition - Feb 4, 2008 ...methocarbamol,oxaliplatin, oxycodone hydrochloride, palonosetron hydrochloride, pantoprazole sodium, pemetrexed disodium and prochlorperazine mesylate. ... Medscape MGI PHARMA Issues Statement - Nov 29, 2007 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA to Present at the 23rd Annual JPMorgan Healthcare … - Jan 13, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... businesswire.com MGI PHARMA REPORTS FIRST QTR '06 TOTAL REVENUE OF $78.2 … - Jun 1, 2006 During the first quarter of 2006, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $63.3 million compared to $57.2 million in the first ... Free with registration - Biotech Financial Reports - AccessMyLibrary.com MGI PHARMA First Quarter 2005 Financial Results Conference Call to Be... - Apr 13, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate capsules), Salagen(R) Tablets (pilocarpine ... businesswire.com MGI PHARMA Reports Fourth Quarter and Full Year 2006 Financial … - Feb 7, 2007 During the fourth quarter of 2006, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $49.6 million compared to $67.0 million in the fourth ... Genetic Engineering News - Genetic Engineering News (press release) Gliadel(R) Wafer Demonstrates Long-Term Survival Benefit for Patients... - Mar 8, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com FDA Approves Palonosetron for Prevention of Postoperative Nausea and ... - Mar 3, 2008 WOODCLIFF LAKE, NJ -- March 3, 2008 -- The US Food and Drug Administration (FDA) has approved palonosetron hydrochloride (Aloxi) injection for the ... DG News MGI PHARMA Fourth Quarter and Year End 2004 Financial Results; … - Feb 2, 2005 MGI PHARMA markets Aloxi(TM) (palonosetron hydrochloride) injection, Salagen(R) Tablets (pilocarpine hydrochloride), and Hexalen(R) (altretamine) capsules ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Reports First Quarter 2006 Financial Results; First... - Apr 19, 2006 During the first quarter of 2006, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $63.3 million compared to $57.2 million in the first ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA and HELSINN Announce Aloxi(R) sNDA Approval Allowing … - Sep 4, 2007 ...a supplemental New Drug Application (sNDA) for Aloxi(R) (palonosetron hydrochloride) Injection by the United States Food and Drug Administration (FDA). ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA Reports Fourth Quarter and Fiscal 2004 Results - Dec 31, 2005 ...including Aloxi(R) (palonosetron hydrochloride) injection sales of $159.3 million. GAAP net loss for 2004 was $85.7 million, or $1.23 per diluted share. ... businesswire.com MGI PHARMA Receives Approvable Letter for Saforis(TM) (Glutamine) … - Oct 12, 2006 MGI PHARMA markets Aloxi[R] (palonosetron hydrochloride) Injection, Dacogen[TM] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Reports Third Quarter 2007 Financial Results.(Financial … - Oct 17, 2007 During the third quarter of 2007, sales of Aloxi([R]) (palonosetron hydrochloride) Injection totaled $66.3 million compared to $70.4 million in the third ... $4.95 - Business Wire - ECNext MGI Pharma Buys Out Guilford For $177.5M In Cash, Stock - Jul 22, 2005 Moulder noted that MGI's Aloxi (palonosetron hydrochloride) for chemotherapy-induced nausea and vomiting (CINV) has more sales potential - in 2003, ... BioWorld Online - BioWorld Online Dacogen NDA Accepted for Filing by FDA. - Jan 3, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... $4.95 - Business Wire - ECNext MGI PHARMA and Guilford Pharmaceuticals Announce Expiration of the … - Sep 1, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... $4.95 - Business Wire - ECNext MGI PHARMA To Present at the Bear Stearns 19th Annual Healthcare … - Sep 5, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA To Present at The BMO Capital Markets 7th Annual Focus … - Nov 27, 2007 MGI PHARMA markets Aloxi[R] (palonosetron hydrochloride) Injection, Dacogen[R] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com Company Profile for MGI PHARMA, INC. - Apr 16, 2008 MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® (polifeprosan 20 with carmustine implant) ... businesswire.com MGI PHARMA And SuperGen Provide Regulatory Status Updates For … - Nov 15, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... RedOrbit MGI PHARMA Reports Fourth Quarter and Fiscal 2004 Results. - Feb 9, 2005 ...including Aloxi(R) (palonosetron hydrochloride) injection sales of $159.3 million. GAAP net loss for 2004 was $85.7 million, or $1.23 per diluted share. ... $4.95 - Business Wire - ECNext MGI PHARMA Recognized for Innovation & Growth. - Nov 2, 2006 MGI PHARMA markets Aloxi[R] (palonosetron hydrochloride) Injection, Dacogen[TM] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA to Present at the Piper Jaffray Health Care Conference. - Jan 19, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... $4.95 - Business Wire - ECNext Dacogen(TM) (Decitabine) for Injection Receives US Orphan Drug … - Aug 10, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com Aloxi(R) Phase 3 Data for Post Operative Nausea and Vomiting (PONV) … - Oct 15, 2007 PALO-04-07 is a randomized, multi-center phase 3 clinical trial conducted to evaluate the safety and efficacy of Aloxi(R) (palonosetron hydrochloride) ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA Completes Acquisition of Guilford Pharmaceuticals. - Oct 3, 2005 MGI PHARMA markets Aloxi (palonosetron hydrochloride) injection at a dose of 0.25 mg for the prevention of acute nausea and vomiting associated with initial ... Free with registration - Business Wire - AccessMyLibrary.com Gliadel(R) Wafer Clinical Data Presented at Society for Neuro... - Nov 20, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with ... Free with registration - PR Newswire - AccessMyLibrary.com MGI PHARMA To Present at the 2006 UBS Global Specialty … - Apr 17, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Summarizes Data Presented at the 2007 American Society … - Jun 4, 2007 In addition to two posters, Aloxi(R) (palonosetron hydrochloride) Injection was the subject of a published abstract describing study results that ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA to Present at the Merrill Lynch Global Pharmaceutical, … - Feb 3, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... $4.95 - Business Wire - ECNext MGI PHARMA to Present at the Cowen and Company 27th Annual … - Mar 8, 2007 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA Announces Publication of Phase 3 Data for Saforis(TM) ( … - Jan 17, 2007 MGI PHARMA markets Aloxi[R] (palonosetron hydrochloride) Injection, Dacogen[TM] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com Aquavan(R) (Fospropofol Disodium) Injection Data Presented at … - May 23, 2007 MGI PHARMA markets Aloxi([R]) (palonosetron hydrochloride) Injection, Dacogen([R]) (decitabine) for Injection, and Gliadel([R]) Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com MGI Pharma seeks broader market for anti-nausea drug - May 7, 2007 Helsinn Healthcare, a privately owned Swiss pharmaceutical group that licenses some of the ingredients of Aloxi (palonosetron hydrochloride). ... Twin Cities Business Journal MGI PHARMA To Present at the Lehman Brothers 9th Annual Global … - Mar 3, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA to Present at the Pacific Growth Equities Life Sciences … - Jun 1, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... $4.95 - Business Wire - ECNext Finance; Oncology-focused biopharmaceutical company reports 4Q,... - Mar 11, 2005 ...announced that total revenue for 2004 was $195.7 million, including Aloxi (palonosetron hydrochloride) injection sales of $159.3 million. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones A press release distributed by PR Newswire Europe - Feb 28, 2005 ...announce the signing of an agreement granting GALENICA the exclusive License and Distribution rights for ALOXI(R) (Palonosetron hydrochloride) in GREECE ... prnewswire.co.uk Investment Alert for HSXI! June 27, 2006. - Jun 27, 2006 MGI PHARMA, INC. recently announced it has provided a summary of Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and ... Free with registration - M2 Presswire - AccessMyLibrary.com MGI PHARMA Third Quarter 2005 Financial Results Conference Call to … - Oct 19, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) wafer (polifeprosan 20 with carmustine implant) in the United States. ... businesswire.com MGI PHARMA To Present at the Baird 2006 Growth Stock Conference. - May 4, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA's Analyst and Investor Event to Be Webcast on July 25, … - Jul 19, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Third Quarter 2007 Financial Results Conference Call to … - Oct 17, 2007 MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine ... businesswire.com Notice of Conversion Right for Senior Subordinated Convertible Notes ... - Dec 26, 2007 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA Fourth Quarter and Year End 2006 Financial Results … - Feb 7, 2007 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... Genetic Engineering News - Genetic Engineering News (press release) Dr. Gerard T. Kennealey Joins MGI PHARMA as Senior Vice President, … - May 25, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA to Present at the JP Morgan 25th Annual Healthcare … - Jan 3, 2007 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA Announces Publication of Phase 3 Data for Dacogen(TM) ( … - Apr 18, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA To Present at the Baird 2006 Growth Stock Conference - May 10, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... businesswire.com MGI PHARMA UNVEILS DACOGEN (DECITABINE) FOR INJECTION. - Jul 1, 2006 MGI PHARMA markets Aloxi(r) (palonosetron hydrochloride) Injection, Dacogen(tm) (decitabine) for Injection and Gliadel (r) Wafer (polifeprosan 20 with ... Free with registration - Biotech Business - AccessMyLibrary.com MGI PHARMA To Present at the Bank of America Specialty … - Aug 3, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA's Analyst and Investor Event to Be Webcast on July 25, … - Jul 25, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... businesswire.com Dr. James Armitage Appointed to MGI PHARMA Board of Directors. - Jul 26, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com AkaRx and MGI PHARMA Announce Closing of Development and … - Oct 11, 2007 MGI PHARMA markets Aloxi[R] (palonosetron hydrochloride) Injection, Dacogen[R] (decitabine) for Injection, and Gliadel[R] Wafer (polifeprosan 20 with ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Appoints William F. Spengler As CFO. - Apr 24, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA to Present at the Bear Stearns 18th Annual Healthcare … - Sep 5, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... $4.95 - Business Wire - ECNext |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |